Eli Lilly plots $2.1B manufacturing expansion at America's crossroads, with 500 new hires

URLhttps://www.fiercepharma.com/manufacturing/eli-lil
SourceFierce Pharma
Date Published05/25/2022
Author NameFraiser Kansteiner
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Eli Lilly and Company
Parent companyEli Lilly and Company
Type of work Manufacturing
Reshoring category:Reshoring
Total number of jobs (added or to be added):500
Year reshoring announced:2022
Domestically, the work will be done:In-house
Capital investment ($):2100
City reshored to:Indianapolis
State(s) reshored to:IN
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoreddrugs, genetic medicines
What domestic positive factors made reshoring more attractive?Government Incentives, Skilled workforce availability/training
Find Reshoring Articles